glp-1 and insulin, diabetes type 2 theraphy

glucagon peptide incretin receptor secretion pancreas beta cells insulin glucose metabolism agonist analog exenatide liraglutide semaglutide pharmacokinetics pharmacodynamics efficacy bioavailability halflife glycemic control type diabetes satiety weight loss cardiovascular neuroprotection enzyme degradation dipeptidyl peptidase4 dpp4 gastrointestinal subcutaneous injection additional scientific words glp1 endocrinology glucoregulation camp islet therapeutic